Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.

Richard BuusIvana SestakStephen BarronTony LoughmanBozena FenderCesar Lopez RuizPeter Dynoodt Chan-Ju Angel WangDes O'LearyWilliam M GallagherMitch DowsettJack M Cuzick

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

OMm, OMclin1, and OMclin2 were highly prognostic for early and late DR in women with early-stage ER-positive breast cancer receiving 5 years' endocrine therapy. In TransATAC, OMclin1 and the OncoMasTR Risk Score (OMclin2) were superior to RS in identifying patients at increased risk of DR.

Keyphrases

estrogen receptor
early stage
positive breast cancer
end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
editorial comment
prognostic factors
mesenchymal stem cells
lymph node
breast cancer cells